China Botanic Pharmaceutical Inc. Announces Receipt of Notice of Failure to Satisfy Continued Listing Requirements

 China Botanic Pharmaceutical Inc. Announces Receipt of Notice of Failure to
                    Satisfy Continued Listing Requirements

PR Newswire

HARBIN, China, Feb. 5, 2013

HARBIN, China, Feb. 5, 2013 /PRNewswire/ -- China Botanic Pharmaceutical Inc.
(AMEX: CBP) (formerly Renhuang Pharmaceuticals, Inc.) ("China Botanic" or the
"Company"), a developer, manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China,
announced today that on January 31, 2013, the Company received a notice of
failure to satisfy continued listing standards (the "Letter") from the NYSE
MKT LLC (the "Exchange").

The Letter indicates that although the Company has resolved the Audit
Committee continued listing deficiency referenced in the letter from the
Exchange dated January 12, 2013, the staff of the NYSE MKT Corporate
Compliance Department (the "Compliance Department") has determined that based
upon its review of the Form NT 10-K filed on January 30, 2013 and subsequent
discussions, the Company will be unable to timely file its Form 10-K for the
period ended October 31, 2013 ("Form 10-K") by February 14, 2013. In the
Company's Form NT 10-K, the Company indicated that management has encountered
delays in completing the Company's consolidated financial statements and
corresponding delays in completing its annual audit. As such, information
necessary for the filing of a complete and accurate report on Form 10-K cannot
not be gathered within the prescribed time period without unreasonable effort
and expense. The Company remains committed to completing its Form 10-K at the
earliest possible time, but does not currently anticipate its completion
within the fifteen calendar days following the prescribed due date. The timely
filing of the Form 10-K is a condition for the Company's continued listing on
the Exchange under Sections 134 and 1101 of the NYSE MKT LLC Company Guide
(the "Company Guide").

In order to maintain its listing, the Company must submit a plan of compliance
(the "Compliance Plan") by February 14, 2013 advising of actions that Company
has taken or will take to comply with Sections 134 and 1101 of the Company
Guide by May 1, 2013. The Compliance Department will evaluate the Compliance
Plan and make a determination as to whether or not to accept the Compliance
Plan by May 1, 2013. In the event the Compliance Plan is accepted, the Company
will remain listed during the plan period and will be subject to periodic
review to determine whether progress is being made pursuant to the Compliance
Plan. In the event that a Compliance Plan is not submitted, accepted or
progress is not made under the Compliance Plan during the plan period, the
Exchange staff may initiate delisting proceedings in accordance with Section
1010 and Part 12 of the Company Guide.

The Company intends to submit a Compliance Plan by February 14, 2013 and
continues its efforts to file the Form 10-K at the earliest possible time.

About China Botanic Pharmaceutical Inc.

China Botanic Pharmaceutical Inc. is engaged in the research, development,
manufacturing, and distribution of botanical products, bio-pharmaceutical
products, and traditional Chinese medicines ("TCM"), in the People's Republic
of China. All of the Company's products are produced at its three
GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The
Company distributes its botanical anti-depression and nerve-regulation
products, biopharmaceutical products, and botanical antibiotic and OTC TCMs
through its network of over 3,000 distributors and over 70 sales centers
across 24 provinces in China. For more information, please visit

Safe Harbor Statement

This press release contains certain statements that may include
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are based upon management's
beliefs, assumptions and expectations of the Company's future operations and
financial performance, taking into account the information currently available
to management. These statements are not statements of historical fact.
Forward-looking statements involve risks and uncertainties, some of which are
not currently known that may cause actual results, performance or financial
condition to be materially different from the expectations of future results,
performance or financial condition expressed or implied in any forward-looking
statements. These forward-looking statements are based on current plans and
expectations and are subject to a number of uncertainties including, butnot
limited to, the Company's ability to manage expansion of its operations
effectively, and other factors detailed in the Company's annual report on Form
10-K and other filings with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information presented herein.

Company Contact:

China Botanic Pharmaceutical Inc.
Ms. Portia Tan, IR Contact
Tel: 86-451-8260-2162

SOURCE China Botanic Pharmaceutical Inc.

Press spacebar to pause and continue. Press esc to stop.